– USA, CA – Nuvig Therapeutics, Inc., a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the appointment of Dr. David Woodhouse ( Ph.D.) as CEO and member of the Board of Directors and Dr. James Mackay (Ph.D.) as Independent Board Chair.
About Dr. David Woodhouse
Dr. Woodhouse brings more than 23 years of experience in the biopharmaceutical industry as a scientist and expert in strategy, finance, and capital development for growing biotechnology companies. Before Nuvig, he was Chief Executive Officer and a director of NGM Biopharmaceuticals, Inc., where he guided the company through multiple clinical milestones and strategic partnerships. Before becoming CEO, Dr. Woodhouse was NGM’s Chief Financial Officer for more than three years. Previous to NGM, he was Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking at Goldman Sachs & Co. LLC. Earlier in his career, David worked at Dynavax Technologies and as a research assistant at Amgen Inc. Dr. Woodhouse holds a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from Tuck School of Business at Dartmouth, and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.
About Dr. James Mackay
Dr. Mackay is a veteran biotechnology executive with expertise spanning drug development, corporate strategy, and building high-performing teams. He is currently CEO of Kateran Consulting and has held multiple leadership roles across the industry, including CEO roles at Ardea Bioscience and Aristea Therapeutics, as well as numerous executive positions at AstraZeneca.
About Nuvig Therapeutics
Nuvig Therapeutics is a clinical-stage biotechnology company pioneering precisely engineered Fc-based therapeutics to redefine the treatment of chronic inflammatory and autoimmune diseases. The company’s lead candidate is NVG-2089, an engineered Fc fragment that is designed to mimic the binding of sialylated IgG to type II Fc receptors. Nuvig’s BESTech platform builds on this approach to create multi-functional biologics that can be applied across a range of autoimmune and inflammatory indications. Nuvig is based in Menlo Park, California, and backed by leading life science investors.
For more information: https://www.nuvigtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.